Back to Previous Page
New SearchHide Search
Erenumab is designed to specifically block the CGRP receptor, which plays a critical role in migraine activation. It is being co-developed by Novartis and Amgen.
This media asset is free for editorial broadcast, print, online and radio use. It is restricted for other purposes.
This file is for journalists only. Please fill out the form below to request access.
By submitting this field I verify that I am a journalist.
You are here
This site is intended for a global audience.